ERBB2 and gastric cancer: More recently, combining pembrolizumab with trastuzumab and chemotherapy for HER2-positive gastric cancer resulted in a further improvement in objective response rates (ORRs) of 74.4% versus 51.9% in a trastuzumab-plus-chemotherapy study arm [14].